Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Key growth drivers and launches continue momentum in H1
H1 key growth driver sales momentum¹
Driving portfolio rejuvenation
Sales
Growth vs. PY
Growth vs. PY
USD Million
USD Million
CC
Entresto
1,675
526
40%
Key growth drivers and launches
49% of IM sales, growing 24% in H1
sacubitnivalsartan
Cosentyx
(secukinumab
AimovigⓇ
2,228
354
16%
49%
KesimptaⓇ
MayzentⓇ
zolgensma 634
259
63%
PiqrayⓇ
42%
PROMACTA® 976
151
16%
XiidraⓇ
(eltrombopag)
LutatheraⓇ
JAKAVI
761
133
14%
ruxolitinib
32%
Kesimpta
116
116
nm
(ofatumumab)
24%
KISQALI
420
100
28%
ribociclib
Xolair
690
94
9%
Omalizumab
ILARIS
503
90
20%
(canakinumab)
KymriahⓇ
KisqaliⓇ
llarisⓇ
ZolgensmaⓇ
Jakavi®
Tafinlar+MekinistⓇ
PromactaⓇ
EntrestoⓇ
KYMRIAH
298
87
35%
(tisagenlecleucel)
818
81
7%
CosentyxⓇ
Other¹
Tafinlar +Mekinist
MAYZENT.
124
(siponimod) tablets
24
H1 2018
H1 2019
H1 2020
H1 2021
60
89%
nm not meaningful
1. Includes Xolair®, Beovu®, AdakveoⓇ, Luxturna Ⓡ, Tabrecta®, Enerzair ®, AtecturaⓇ and LeqvioⓇ
1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure. An explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this
Release refer to same period in prior year.
42 Investor Relations | Q2 2021 Results
U NOVARTIS | Reimagining MedicineView entire presentation